Muscle Is the Longevity Drug: Why Rapamycin Failed Humans

Two major trials say yes for the endpoints they measured. RAPA-EX-01 (Stanfield & Kaeberlein) gave 40 sedentary older adults 6mg of rapamycin weekly for 13 weeks. Placebo beat rapamycin on chair stands, grip strength, 6-minute walk, and SF-36 quality-of-life scores. Epigenetic age was unchanged and adverse events were 57% higher. PEARL ran 114 adults aged 50–85 on 5–10mg weekly for 11 months and found no reduction in visceral fat versus placebo, with negative effects on bone mineral density, HbA1c (males), and gut microbiome. Physical function was unchanged.

Metformin activates AMPK, which is your body's energy-crisis sensor. Activating AMPK tells cells they are starving — and starving cells do not prioritize protein synthesis. The MASTERS trial (Walton 2019) put older adults on 1700mg metformin or placebo while doing 14 weeks of resistance training. Placebo gained 1.6kg of lean mass; metformin gained 0.9kg. That is a 44% blunting of the same training stimulus. Konopka 2019 found a similar ~50% blunting of aerobic VO₂max improvements. Mechanistically, metformin upregulates myostatin via AMPK→FoxO3a (Kang 2022).

Lab mice live in cages, eat ad libitum, never resistance-train, and almost never reach functional limits before they die. Their cause of death is typically cancer or organ failure, not the frailty cascade that kills most humans. Suppressing mTORC1 in a sedentary mouse modestly reduces cancer incidence and extends median lifespan. Suppressing mTORC1 in a 70-year-old human accelerates the most important cause of human mortality — sarcopenia and frailty — because mTORC1 is required to build and maintain the muscle that prevents falls, hospitalization, and the downstream cascade.

A lot. Leong 2015 (PMID 25982160) tracked roughly 140,000 adults across 17 countries. Every 5kg drop in grip strength was associated with a 16% higher risk of all-cause mortality and a 17% higher risk of cardiovascular mortality. García-Hermoso 2018 (systematic review) reported every 5kg increase predicted a 31% lower all-cause mortality. Grip strength outperforms blood pressure, BMI, and most blood markers as a single-variable mortality predictor in older adults — partly because it is a proxy for total muscular reserve.

The simplest interpretation: build muscle while you are young (more myonuclei = lifetime muscle memory), maintain it as you age via resistance training 3–4× weekly with progressive overload, eat adequate protein (1.6–2.2 g/kg/day), and stop assuming a drug can substitute for the work. mTORC1-suppression compounds (rapamycin, metformin) actively work against this goal. Myostatin inhibitors and selective androgen modulators are the more interesting pharmacological future — they support muscle accrual rather than blocking the same pathway that maintains it.